Get notified when NMTC files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Restatement (new) — Company restated Q2 FY2026 financials for revenue recognition errors discovered after a customer questioned invoices; net loss increased $0.3M.
  • Material Weakness (worsened) — Second material weakness identified in revenue recognition controls (purchase order modifications, shipping documentation, shipment reconciliations), in addition to the previously disclosed segregation-of-duties weakness.
  • Going Concern (unchanged) — Filing states that conditions raise substantial doubt about the company's ability to continue as a going concern. The same disclosure appeared in the baseline filing.
NASDAQ: NMTC NEUROONE MEDICAL TECHNOLOGIES Corp 10-Q/A

NMTC restates Q2 FY2026 on $0.5M revenue error; second material weakness disclosed

Filed June 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2026 · ~2 min read

Key Financials

SEC XBRL

Period financials are unchanged from the original 10-Q (same period end Mar 31, 2026). This amendment updates disclosure only — see the diff below.

Key Changes

  • high

    Company restated Q2 FY2026 financials after a customer questioned March 31 invoices; product revenue reduced $0.5M (from $2.4M to $1.9M) and net loss widened $0.3M (from $2.1M to $2.4M) due to improperly recognized shipments under a modified order arrangement.

    Notes: Restatement verify on EDGAR →
  • high

    Second material weakness identified in revenue recognition controls, specifically around review of purchase order modifications, shipping documentation, and shipment reconciliations—the deficiency that caused the restatement.

    Controls & Procedures verify on EDGAR →
  • high

    Accumulated deficit increased from $82.1M to $82.4M as of March 31, 2026 due to restatement adjustments; going concern disclosure updated to reflect the higher deficit.

    Notes: Going Concern verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ESI 10-Q) is open in full — no account needed.

Partner

Trade NMTC commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Source-verified from EDGAR · Narrative written by AI · Jul 30, 2026 · How we verify